A Practical Method for Targeted Library Design Balancing Lead‐like Properties with Diversity

Choosing the right compounds to synthesise from large virtual combinatorial libraries is a current challenge for the pharmaceutical industry. Herein we describe a highly optimised method that aligns lead‐like properties with compound diversity. The methods are illustrated by considering a two‐dimensional library based on the interesting spirocyclic bis‐azetidine template.

[1]  Ramon Camacho,et al.  2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[2]  A. Pandey,et al.  Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes. , 2001, Bioorganic & medicinal chemistry letters.

[3]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[4]  Andrew M Davis,et al.  Components of successful lead generation. , 2005, Current topics in medicinal chemistry.

[5]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[6]  John Steele,et al.  Drug-like properties: guiding principles for design - or chemical prejudice? , 2004, Drug discovery today. Technologies.

[7]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[8]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[9]  Stephen D. Pickett,et al.  Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening , 2004 .

[10]  Andrew C. Good,et al.  An Empirical Process for the Design of High-Throughput Screening Deck Filters , 2006, J. Chem. Inf. Model..

[11]  Phillip Gribbon,et al.  High-throughput drug discovery: what can we expect from HTS? , 2005, Drug discovery today.

[12]  Garry Pairaudeau,et al.  Synthesis of novel 2,6-diazaspiro[3.3]heptanes , 2007 .

[13]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[14]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[15]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[16]  Andrew M. Davis,et al.  Design kombinatorischer Leitstruktur‐Bibliotheken , 1999 .

[17]  Jeremy N. Burrows,et al.  4.18 – Lead Discovery and the Concepts of Complexity and Lead-Likeness in the Evolution of Drug Candidates , 2007 .

[18]  Michael J. Stocks,et al.  A novel rearrangement reaction conversion of 3-(chloromethyl)azetidin-2-ones to azetidine-3-carboxylic acid esters , 1991 .

[19]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[20]  Bo Nordén,et al.  Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. , 2008, Journal of medicinal chemistry.

[21]  Judith Provis.  Compound Management and Enhancement Activities in AstraZeneca , 2005 .

[22]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[23]  Wolfgang H. B. Sauer,et al.  Size doesn't matter: Scaffold diversity shape diversity, and biological activity of combinatorial libraries , 2003 .

[24]  J A Landro,et al.  HTS in the new millennium: the role of pharmacology and flexibility. , 2000, Journal of pharmacological and toxicological methods.

[25]  M. Maccoss,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes. , 2001, Bioorganic & medicinal chemistry letters.

[26]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[27]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[28]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[29]  Tomio Yamakawa,et al.  A New Reduction of Some Carboxylic Esters with Sodium Borohydride and Zinc Chloride in the Presence of a Tertiary Amine , 1991 .

[30]  Irini Akritopoulou-Zanze,et al.  Topography-biased compound library design: the shape of things to come? , 2007, Drug discovery today.

[31]  K. R. Oldenburg,et al.  Chapter 30 – Current and Future Trends in High Throughput Screening for Drug Discovery , 1998 .

[32]  Erick M Carreira,et al.  2,6-Diazaspiro[3.3]heptanes: synthesis and application in Pd-catalyzed aryl amination reactions. , 2008, Organic letters.

[33]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[34]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[35]  C. Wermuth.  Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.

[36]  Daniel Swern,et al.  Activated Dimethyl Sulfoxide: Useful Reagents for Synthesis , 1981 .

[37]  J P Sanchez,et al.  Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. , 1990, Journal of medicinal chemistry.

[38]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..